Mouse Genome Informatics
hm1
    Scn5atm1Care/Scn5atm1Care
FVB.129P2-Scn5atm1Care
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
mortality/aging
• authors state all mice die in utero, no specific time of lethality provided


Mouse Genome Informatics
ht2
    Scn5atm1Care/Scn5a+
FVB.129P2-Scn5atm1Care
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
mortality/aging
N
• unlike human patients with a similar mutation, heterozygotes do not display sudden cardiac death (J:128657)

cardiovascular system
• significantly slower heart rate
• flecainide induced extreme sinus bradycardia and/or sinus arrest in 4 of 6 mice compared to 0 of 6 in wild-type controls
• epicardial mapping indicates slower conduction (increased activation time, reduced transverse conduction velocity) in the right ventricle but not in the left ventricle
• significant prolongation of the PQ interval
• increase in the flecainide-induced prolongation of the PQ interval compared to wild-type controls
• prolonged QRS duration
• increase in the flecainide-induced prolongation of the QRS interval compared to wild-type controls
• prolonged QTc interval
• more sinus pauses of longer duration
• however, no ventricular arrhythmias are detected
• prolonged action potential duration at frequencies less than 4 Hz and smaller dV/dt(max) at all frequencies tested
• ventricular myocytes show reduced peak sodium current densities and prolonged current decay half-life (at voltages from -45 to -25 mV) at room temperature
• upstroke velocity (dV/dt(max)) of the elicited action potential is reduced by 31% at -120 mV
• the current density of persistent sodium currents is significantly larger at voltages between -90 and -10 mV